Media coverage about Exelixis (NASDAQ:EXEL) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exelixis earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.9749819814512 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern’s rankings:
- 4 Biotech Stocks to Watch in the New Year (finance.yahoo.com)
- Recent Insiders Bustle: Exelixis, Inc. (EXEL), Urban Outfitters, Inc. (URBN) – Market Movers (financialqz.com)
- Exelixis (EXEL) Amends Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in … – StreetInsider.com (streetinsider.com)
- The Secret Sauce Behind Exelixis, Inc.’s 12% Move Higher in December – Motley Fool (fool.com)
- Exelixis Announces Amendment to Clinical Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic … (businesswire.com)
Shares of Exelixis (NASDAQ:EXEL) traded down $0.27 during mid-day trading on Friday, hitting $31.62. The stock had a trading volume of 2,243,300 shares, compared to its average volume of 2,430,000. The firm has a market capitalization of $9,350.00, a PE ratio of 64.53, a price-to-earnings-growth ratio of 0.95 and a beta of 1.88. Exelixis has a 12 month low of $14.90 and a 12 month high of $32.50.
Several equities analysts have commented on EXEL shares. Stifel Nicolaus reiterated a “hold” rating and issued a $26.00 target price on shares of Exelixis in a research report on Thursday, September 7th. Piper Jaffray Companies reiterated a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research report on Sunday, September 10th. Oppenheimer reiterated a “hold” rating on shares of Exelixis in a research report on Sunday, September 10th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price (up from $28.00) on shares of Exelixis in a research report on Tuesday, September 12th. Finally, Royal Bank of Canada started coverage on Exelixis in a research report on Thursday, September 14th. They issued an “outperform” rating and a $32.00 target price for the company. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $32.13.
TRADEMARK VIOLATION NOTICE: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3127742/exelixis-exel-earns-daily-media-sentiment-rating-of-0-20.html.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.